Literature DB >> 11712791

Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management.

A Gadducci1, S Cosio, A Fanucchi, A R Genazzani.   

Abstract

In ovarian cancer patients the poor nutritional status and cachexia are caused by the metabolic effects of the enlarging tumor masses and bowel obstruction. These patients may have a high resting energy expenditure due to increase in Cori cycle activity, glucose and triglyceride-fatty acid cycling and gluconeogenesis. Biochemical mediators of cachexia include cytokines, such as tumor necrosis factor and interleukin-6, and tumor-produced catabolic factors, such as lipid-mobilizing factor, proteolysis-inducing factor, and anemia-inducing factor. Mechanisms involved in the pathogenesis of obstruction may include extrinsic occlusion of the bowel due to pelvic, mesenteric omental masses, or intestinal motility disorders due to infilor tration of the mesentery or bowel muscle and nerves. The relief of malnutrition and cachexia may be attempted through nutritional support, pharmacological approach (megestrol acetate, cyclooxygenase inhibitors) and palliative treatment of bowel obstruction. Very few agents have been demonstrated to have true anticachectic activity, so future research should be addressed to the identification of drugs able to block the activity of tumor-produced catabolic factors. The decision regarding optimum management of bowel obstruction should be individualized. Krebs' and Goplerud's score (based on age, nutritional status, tumor status, ascites, previous chemotherapy and irradiation) seems to offer reliable eligibility criteria for those patients who can benefit from surgery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712791

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  L M Hess; R Barakat; C Tian; R F Ozols; D S Alberts
Journal:  Gynecol Oncol       Date:  2007-08-06       Impact factor: 5.482

2.  Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer.

Authors:  V Asher; J Lee; A Bali
Journal:  Med Oncol       Date:  2011-07-07       Impact factor: 3.064

Review 3.  The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  J Mol Med (Berl)       Date:  2013-09-21       Impact factor: 4.599

4.  Pre- and post-diagnosis body mass index, weight change, and ovarian cancer mortality.

Authors:  Yang Zhou; Melinda L Irwin; Harvey A Risch
Journal:  Gynecol Oncol       Date:  2010-11-23       Impact factor: 5.482

5.  Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia.

Authors:  Tugba Yavuzsen; Declan Walsh; Mellar P Davis; Jordanka Kirkova; Tao Jin; Susan LeGrand; Ruth Lagman; Lesley Bicanovsky; Bassam Estfan; Bushra Cheema; Abdo Haddad
Journal:  Support Care Cancer       Date:  2009-04-07       Impact factor: 3.603

6.  Modulation of the nuclear factor-kappa B (NF-κB) signalling pathway by glutamine in peritoneal macrophages of a murine model of protein malnutrition.

Authors:  Fabiana da Silva Lima; Marcelo Macedo Rogero; Mayara Caldas Ramos; Primavera Borelli; Ricardo Ambrósio Fock
Journal:  Eur J Nutr       Date:  2012-08-26       Impact factor: 5.614

7.  Pre-operative hypoalbuminemia is a major risk factor for postoperative complications following rectal cancer surgery.

Authors:  Varut Lohsiriwat; Darin Lohsiriwat; Wiroon Boonnuch; Vitoon Chinswangwatanakul; Thawatchai Akaraviputh; Narong Lert-Akayamanee
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

Review 8.  Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis.

Authors:  Sarah A Purcell; Sarah A Elliott; Candyce H Kroenke; Michael B Sawyer; Carla M Prado
Journal:  Curr Oncol Rep       Date:  2016-02       Impact factor: 5.075

9.  Cachexia and aging: an update based on the Fourth International Cachexia Meeting.

Authors:  J E Morley; S D Anker; W J Evans
Journal:  J Nutr Health Aging       Date:  2009-01       Impact factor: 4.075

10.  Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass.

Authors:  Alex R Straughn; Natia Q Kelm; Sham S Kakar
Journal:  Front Cell Dev Biol       Date:  2021-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.